Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Clinical trial NCT02553941 · COMPLETED

Trial details

NCT number: NCT02553941
Sponsor: Brian Jonas
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Refractory Anemia With Excess Blasts in Transformation Secondary Myelodysplastic Syndrome

Start date: 2016-05-17
Primary completion: 2019-05-25
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.